



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Ur Metser
✉ Ur.metser@uhn.ca

RECEIVED 19 October 2023
ACCEPTED 20 October 2023
PUBLISHED 01 November 2023

CITATION
Murad V, Kulanthaivelu R, Ortega C,
Veit-Haibach P and Metser U (2023)
Corrigendum: Standardized classification
schemes in reporting oncologic PET/CT.
Front. Med. 10:1324108.
doi: 10.3389/fmed.2023.1324108

COPYRIGHT
© 2023 Murad, Kulanthaivelu, Ortega,
Veit-Haibach and Metser. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted which
does not comply with these terms.

Corrigendum: Standardized classification schemes in reporting oncologic PET/CT

Vanessa Murad^{1,2}, Roshini Kulanthaivelu^{1,2}, Claudia Ortega^{1,2},
Patrick Veit-Haibach^{1,2} and Ur Metser^{1,2*}

¹Molecular Imaging Division, Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, ON, Canada, ²University Medical Imaging Toronto, University of Toronto, Toronto, ON, Canada

KEYWORDS

PET, Deauville, Krenning, PROMISE, immunotherapy, head and neck cancer

A corrigendum on Standardized classification schemes in reporting oncologic PET/CT

by Murad, V., Kulanthaivelu, R., Ortega, C., Veit-Haibach, P., and Metser, U. (2023). *Front. Med.* 9:1051309. doi: 10.3389/fmed.2022.1051309

In the published article, there was an error regarding the definition of disease progression according to PERCIMT criteria.

A correction has been made to **2. Reporting schemes and classifications, 2.1. Therapy response assessment with 18F-FDG PET, 2.1.4. PET Response Evaluation Criteria for Immunotherapy (PERCIMT)**, paragraph 2.

This sentence previously stated:

“Disease progression is determined in the following 3 scenarios: (1) when there are 4 or more new lesions measuring less than 10 mm in their functional diameter, (2) when there are 3 or more new lesions also with functional diameter below 10 mm, or (3) when there are 2 or more new lesions with a functional diameter greater than 15 mm.”

The corrected sentence appears below:

“Disease progression is determined in the following 3 scenarios: (1) when there are 4 or more new lesions measuring less than 10 mm in their functional diameter, (2) when there are 3 or more new lesions with functional diameter greater than 10 mm, or (3) when there are 2 or more new lesions with a functional diameter greater than 15 mm.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.